Akte Therapeutics
Biotechnology Research
Pioneering exosome delivered epigenetic therapies for monogenic diseases
About us
Akte Therapeutics is developing epigenetic therapies to boost protein production to halt/reverse monogenic diseases. Our platform overcomes the limitations of existing therapeutic approaches to provide treatments for patients in need.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Sydney
- Type
- Privately Held
- Founded
- 2023
Locations
-
Primary
Get directions
Sydney, AU